Drug-like antibodies with low immunogenicity in human panels designed with Latent-X2
Published:Dec 23, 2025 11:17
•1 min read
•ArXiv
Analysis
This article reports on the development of drug-like antibodies with low immunogenicity using a method called Latent-X2. The source is ArXiv, indicating a pre-print or research paper. The focus is on creating antibodies suitable for therapeutic use in humans, minimizing the risk of immune responses.
Key Takeaways
- •Focus on creating therapeutic antibodies.
- •Emphasis on low immunogenicity to reduce adverse immune reactions.
- •Utilizes the Latent-X2 method for antibody design.
- •Published on ArXiv, suggesting early-stage research.
Reference
“”